Clinical and molecular response to alpha1‐oleate treatment in patients with bladder cancer
These dose-dependent anti-tumor effects of alpha1-oleate are promising and support the potential of alpha1-oleate treatment in patients with NMIBC.
Authors
- Marek Babjuk
- Parisa Esmaeili
- Shahram Ahmadi (ORCID: https://orcid.org/0000-0001-5069-7131)
- Inès Ambite (ORCID: https://orcid.org/0000-0003-1470-671X)
- A. Brisuda (ORCID: https://orcid.org/0000-0001-5103-1358)
- Jaromír Háček (ORCID: https://orcid.org/0000-0002-7020-6229)
- Michele Cavalera (ORCID: https://orcid.org/0000-0003-4584-4920)
- Catharina Svanborg (ORCID: https://orcid.org/0000-0001-8145-0553)
- Murphy Lam Yim Wan (ORCID: https://orcid.org/0000-0001-9198-2027)
- Farhan Haq (ORCID: https://orcid.org/0000-0001-9190-4360)
- Samudra Sabari
Institutions
- Lund University (SE)
- Charles University (CZ)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70149
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Cancerfonden
- Vetenskapsrådet
- Kungliga Fysiografiska Sällskapet i Lund
- Horizon 2020 Framework Programme